Showing 1 - 3 results of 3 for search 'Erkut Bahceci', query time: 0.02s Refine Results
  1. 1
    The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

    The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloi... by Jessica K. Altman, Alexander E. Perl, Jason E. Hill, Matt Rosales, Erkut Bahceci, Mark J. Levis

    Published 2021-02-01
    Get full text
    Article
  2. 2
    First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

    First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advance... by Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher

    Published 2016-03-01
    Get full text
    Article
  3. 3
    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

    A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller

    Published 2018-04-01
    Get full text
    Article

Search Tools: